ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,463.54
      0.08%
      US Tech 100
      18,493.20
      -0.14%
      Dow Jones
      40,539.93
      -0.12%
      Brent Oil
      78.885
      -0.33%
      Bitcoin
      66,389.20
      -0.65%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Marker Therapeutics Inc (MRKR) Quote

      Marker Therapeutics Inc

      Marker Therapeutics Inc (MRKR)

      NASDAQ
      5.125
      -0.325
      (-5.96%)
      Closed July 29 4:00PM
      Delayed by 15 minutes
      5.125
      0.00
      (0.00%)
      After Hours: 4:06PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      5.125
      Bid
      3.66
      Ask
      6.00
      Volume
      12,367
      5.08 Day's Range 5.37
      2.40 52 Week Range 6.96
      Market Cap
      45.71M
      Previous Close
      5.45
      Open
      5.35
      Last Trade
      2
      @
      5.02
      Last Trade Time
      Financial Volume
      $ 63,803
      VWAP
      5.1591
      Average Volume (3m)
      21,888
      Shares Outstanding
      8,919,095
      Dividend Yield
      -
      PE Ratio
      -5.54
      Earnings Per Share (EPS)
      -0.92
      Revenue
      3.31M
      Net Profit
      -8.24M

      About Marker Therapeutics Inc

      Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Business Services, Nec
      Website
      www.markertherapeutics.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      2006
      Marker Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRKR. The last closing price for Marker Therapeutics was $5.45. Over the last year, Marker Therapeutics shares have traded in a share price range of $ 2.40 to $ 6.96.

      Marker Therapeutics currently has 8,919,095 shares outstanding. The market capitalization of Marker Therapeutics is $48.61 million. Marker Therapeutics has a price to earnings ratio (PE ratio) of -5.54.

      MRKR Latest News

      More News

      FeaturedCannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

      12 hours ago

      Form 8-K - Current report

      June 12 2024
      Edgar (US Regulatory)

      Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

      May 17 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 15 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 15 2024
      Edgar (US Regulatory)

      Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

      Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada...

      April 08 2024
      GlobeNewswire Inc.

      Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

      Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following...

      March 25 2024
      GlobeNewswire Inc.

      Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

      HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

      March 22 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      March 01 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      February 26 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.0350.6876227897845.095.624.73199585.32647907CS
      4-0.235-4.384328358215.365.994.2501223635.32840527CS
      120.90521.44549763034.225.993.33218884.63708989CS
      260.67515.16853932584.455.993.33198204.47306925CS
      52-1.145-18.26156299846.276.962.4475354.76296632CS
      156-16.875-76.70454545452222.40.67064467895.98946808CS
      260-48.275-90.402621722853.465.40.670662747717.07942998CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      NIPGNIP Group Inc
       16.50
      (82.93%)
      		7.04M
      TIVCTivic Health Systems Inc
      $ 0.7049
      (55.95%)
      		106.15M
      ISPOInspirato Inc
      $ 5.15
      (47.99%)
      		6.24M
      CGTXCognition Therapeutics Inc
      $ 1.32
      (-44.30%)
      		26.32M
      GRIGRI Bio Inc
      $ 0.8334
      (-33.86%)
      		1.14M
      CEROCERo Therapeutics Holdings Inc
      $ 0.1817
      (-29.02%)
      		8.28M
      PRSTPresto Technologies Inc
      $ 0.0499
      (-26.51%)
      		29.32M
      TGLTreasure Global Inc
      $ 1.40
      (-24.32%)
      		80.79k
      NVDANVIDIA Corporation
      $ 111.59
      (-1.30%)
      		248.03M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      SQQQProShares UltraPro Short QQQ
      $ 9.05
      (-0.55%)
      		152.03M
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      TSLATesla Inc
      $ 232.10
      (5.60%)
      		129.2M

      MRKR Discussion

      View Posts
      microcapbiotech microcapbiotech 4 days ago
      Oh OK, Thank You, I did read that. I'm getting old and got a bit confused, I thought it was something new and he was saying that some secondary part of an FDA trial was ending for some reason.
      I feel better, I was think oh no, not another trial ending.
      Thank You Again.
      👍️0
      jobynimble jobynimble 4 days ago
      I posted this last month, maybe you missed it…

      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174589168

      Results of two proposals plus this…

      Item 8.01 Other Events.

      On June 10, 2024, the Company provided notice of its termination of that certain Controlled Equity OfferingSM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which the Company could offer and sell, from time to time at its discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. (the “ATM Offering Program”). The Company is not subject to any termination penalties related to the termination of the ATM Agreement.
      👍️ 1
      microcapbiotech microcapbiotech 4 days ago
      I am getting whiplash from all this up and down and up and down and back and forth.
      👍️0
      microcapbiotech microcapbiotech 4 days ago
      Please elaborate, what cancel the secondary? is this recent news? I have read nothing recently.
      👍️0
      PonkenPlonken PonkenPlonken 5 days ago
      Why would they cancel the secondary if things werent coming together?
      👍️0
      PonkenPlonken PonkenPlonken 5 days ago
      I believe data is right around the corner and things are starting to come together here
      👍️0
      microcapbiotech microcapbiotech 2 weeks ago
      I am glad at your first line of the $ lost isn’t affecting your lifestyle as I retired 14 years ago and am in that same boat. I am sad at your B/E point of $100. I, now in hindsight was an idiot and just kept buying to average down so many times I lost count. The good is you lower your average, the bad is you wind up investing four times as much as you really normally would have. At this point, I just pretend it is all lost, or that it was all a donation to try to cure cancer, no different than my giving to St. Judes Childrens Hospital, other than that, not much to do except wait and hope.
      👍️ 1
      KeithamdMIC KeithamdMIC 2 weeks ago
      Hi Micro and Phantom. My only good thing about Marker is I am retired and the $ that I lost isn’t affecting my lifestyle. It has been a long road down this path with Marker. So yes I’ve spent a lot of time on this board but after the reverse split my brake even point is $100.00 a share. That’s far fetched at this point. I’ve been tempted to buy more at 2 & 3 dollars to lower my average but I finally have waved the white flag. Hopefully I’m wrong and the results of these trials will bring positive results. Take care
      👍️0
      KeithamdMIC KeithamdMIC 2 weeks ago
      You can say that again.
      👍️ 1
      Phantom Lord Phantom Lord 2 weeks ago
      That's the biggest piece of info I want to know also. The fact that they haven't said anything about enrollment numbers kind of worries me. Especially since they already delayed next release from 1st half to 2nd half of this year. No reason the trial shouldn't be fully enrolled and they have all the data they need to be able to move forward to the next phase by the end of the year. I'm starting to think that won't come until early next year though and it just becomes another delay that we have become used to from the company.
      👍️ 1
      microcapbiotech microcapbiotech 2 weeks ago
      Thank You, I'm just doing the wait and hope game. It kind of looks like someone has been accumulating for the last couple of month, but the low volume stinks, need accumulation with huge volume, guess we just have to wait for some good news. I would like to know about How Many Lymphoma patients they are treating. Seems like we both, and others, spent a good chunk of our lives typing on this board.
      👍️ 1
      Phantom Lord Phantom Lord 2 weeks ago
      I'm just waiting to see if they announce some sort of event this month. I was told they were looking to do a research day this month where they would provide a brief update with a more comprehensive review of the lymphoma data in Q2 which, like I previously mentioned, I believe will be closer to Q4. The leather we get into July the more I think the research day was just wishful thinking on the company's part. They don't need a research day anyways, they just need to give us the data they said they would. No more delays.
      👍️0
      learningcurve2020 learningcurve2020 2 weeks ago
      With just 9 million shares outstanding mm's can do anything they want with the share price, but with seriously good news it'd be a rocket ship.
      👍️0
      microcapbiotech microcapbiotech 2 weeks ago
      price slowly going up ... great
      volume ... SUCKS
      Phantom ... have you heard any new news?
      👍️0
      PonkenPlonken PonkenPlonken 3 weeks ago
      MT 601 in Lymphoma is coming in the next 1-2 months and they terminated the ATM offering on June 12.

      People were discussing this stock every day and now everyone stops?
      Will bring huge benefit to patients.
      👍️0
      microcapbiotech microcapbiotech 4 weeks ago
      Message to whoever has been buying the dips for the last couple of weeks, slowly raising the share price.
      KEEP DOING THAT.
      Thank You
      👍️0
      PonkenPlonken PonkenPlonken 1 month ago
      They scoop it up and then sit tightly on the bid after MRKR terminated ATM offering with July ph2 data around and you guys just leave it at that?

      Nobody talks data?
      👍️0
      KeithamdMIC KeithamdMIC 1 month ago
      Hi micro I think your correct. To try and average to a lower break even share price I would think buying shares now would be the key. The news has been somewhat positive on MRKR but it seems that MRKR hasn’t convinced many that the product is viable for those suffering without much hope for remission with traditional medicine. As always when your down somewhat like gambling it’s either walk away or buy more now to swing your share price lower to get back or maybe get in the black with your initial investment. Good luck to all who have been here for years.
      👍️ 1
      PonkenPlonken PonkenPlonken 1 month ago
      11$ is my first target for the readout/potential partner looming. HUUGE Platform.
      Triple digits are possible but assess step by step.
      👍️0
      microcapbiotech microcapbiotech 1 month ago
      Hello, triple digits may be hard, if everything goes perfect for a few more years, then maybe, sorry, just trying to be somewhat rational.
      Great news might bring $20+ in a short time , above $50 would need a TON of revenue I would think.
      👍️0
      KeithamdMIC KeithamdMIC 1 month ago
      I’ve been in this roller coaster for a long time as have Phantom and micro etc. Mostly going down rapidly and up at times very slowly. How do we come back from a 10 to 1 reverse split. I’m sure there are many more that had more shares than I had of MRKR before the reverse split. For me even if MRKR gets bought out the share price would have to hit triple digits a share to break even. I can’t see that happening. Does anyone else?
      👍️0
      PonkenPlonken PonkenPlonken 1 month ago
      get it--- a deal is coming until then price is like a painting in the rain
      keep in mind ph2 readout is coming
      YUUGE platform
      👍️0
      microcapbiotech microcapbiotech 1 month ago
      Now, can we keep climbing? Hope so.
      👍️0
      PonkenPlonken PonkenPlonken 1 month ago
      what are you referring to ?
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      Looks like the one always calling it right gets ignored the most here. Seems to be an investment strategy on many of these iHub boards. LOL
      💩 1 🤡 1
      PonkenPlonken PonkenPlonken 2 months ago
      Given the 8-K---- Wont stay single for much longer. Makes a lot of sense their PFS results and MultiTAA
      Own 7k shares
      👍️ 1
      learningcurve2020 learningcurve2020 2 months ago
      Still no reason to cancel it. Vera may have in his mind to move to the OTC for further cost cutting. The ATM probably can't be used there.

      >>Hopefully this is an indicator that they aren't worried about where the next capital raise is coming from
      👍️0
      Buckboard Buckboard 2 months ago
      Thanks Joby and PL
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      I thought that was pretty interesting also. I could be missing something but it seems odd to terminate it when they could just keep it active but not use it. I'm glad it's gone since I hate ATMs anyways but I still think it's weird as it somewhat acts as a safety net. Hopefully this is an indicator that they aren't worried about where the next capital raise is coming from or at the very least they will have some buyers lined up.
      👍️ 1
      jobynimble jobynimble 2 months ago
      Results of two proposals plus this…

      Item 8.01 Other Events.

      On June 10, 2024, the Company provided notice of its termination of that certain Controlled Equity OfferingSM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which the Company could offer and sell, from time to time at its discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. (the “ATM Offering Program”). The Company is not subject to any termination penalties related to the termination of the ATM Agreement.
      👍️ 2
      jobynimble jobynimble 2 months ago
      8-K out: https://www.sec.gov/ix?doc=/Archives/edgar/data/1094038/000110465924070830/tm2416968d1_8k.htm
      👍️ 1
      PonkenPlonken PonkenPlonken 2 months ago
      again a higher low. Think they start frontrunning the readout.
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      higher lows and some volume
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      things are coming together here
      maybe there is an announcement together here. Dont get why its single given the stellar data .
      👍️0
      InvestorCpt InvestorCpt 2 months ago
      Yeah.... I've had better days
      👍️0
      Buckboard Buckboard 2 months ago
      Yes, now we are all rich.
      👍️ 1
      microcapbiotech microcapbiotech 2 months ago
      ARE WE ALL RICH YET?
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      july p2, excuse me.
      I think it will run earlier in anticipation and/or it doesnt stay single for much longer.
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      No indications we will see any new data in June.
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      Like I said, the company needs to be acquired quickly based on inside knowledge the data looks really promising, or it's over current shareholders.
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      has a loyal buyer. think the june data will make it go, they have outstanding data. Multitarget mutations!
      👍️0
      microcapbiotech microcapbiotech 2 months ago
      Phantom, Thank You for contacting JV and filling us in. Your timeline for event seems the most reasonable.
      I think our main problem is, Nobody has heard of MRKR, Doctors, Patients, Investors.
      I have not and will not sell a single share, but I kind of give up trying to figure this price.
      3 patients, 2 great news and 1 good news, AND IT DOES BASICALLY NOTHING ???
      Have a great summer.
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      That's always my biggest question also. I don't want to be diluted to hell. Every time I bring it up I get the same answer which is the company fully believes they can make it to the end of 2025 with what they have. I was originally skeptical that they could make it that far but the 10Qs do seem to back them up as they have got their spending in check.

      There is a 99% chance we experience some dilution but I previously spoke to Vera about this and he said it would be done on the back of a news release. My guess would be the final lymphoma data which shouldn't be too long. IMO, early next year at the latest but we'll see when we get the enrollment update.

      If the results there are not enough to gain som major SP appreciation then the dilution will be the least of our worries.
      👍️0
      jueles14 jueles14 2 months ago
      Thanks. Vera still working on his CEO communication skills I see haha. Big Q for me as with all biotechs is funding, i.e., can they produce enough good data in the near-term to keep going w/o excessive dilution. I can wait til Q4 if the data’s good; if the H2 data lets down or is still too small sample, we could be in trouble, we’ll see.
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      They're a disaster. Zero energy coming from this company. It feels empty. Without a quick buyout this thing is toast, IMO.
      👍️0
      Buckboard Buckboard 2 months ago
      Thanks
      👍️0
      Phantom Lord Phantom Lord 2 months ago
      I reached out to clarify if we would be getting data in the summer like previously stated or if it would be the "2nd half" of the year which I will generally equate to the latter half of the year. The answer was just 2nd half of the year so I will stick to my assumption that we will get lymphoma data sometime in Q4. My biggest question is if it will be interim or the final readout as I was previously led to believe we could have final data by then. We'll see I guess.

      Additionally, I was told they are planning a research event sometime in July where they should provide more updates. Details on that should be provided sometime next month I would assume.

      So as of now we have this supposed research event, lymphoma data, and the initiation of the Off the Shelf MT401 AML trial to look forward to for the rest of the year. Always a shot at pancreatic updates but the standard announcement on that is they are waiting for grant funds or other non dilutive funds before initiating so I won't count on that news right now
      👍️0
      learningcurve2020 learningcurve2020 2 months ago
      This company filed a 13g

      https://www.nea.com/team?unit=operations#filters
      💩 1 🤡 1
      PonkenPlonken PonkenPlonken 2 months ago
      The buyer never really left here and has excellent data, no cytox..
      👍️0
      InvestorCpt InvestorCpt 2 months ago
      I hope it's just that and not a delay or mediocre results prompting them to keep it quiet
      👍️ 1

      Your Recent History

      NASDAQ
      MRKR
      Marker Therapeutics
      LSE
      PJF
      COIN
      APMGBP
      APM Coin
      Delayed Upgrade Clock